What type of study is this?

This is a Literature Review study.

August 17, 2025Open Access

Role of pharmacogenomics for prevention of hypersensitivity reactions induced by aromatic antiseizure medications

Key Points

Severe cutaneous adverse reactions, including SJS and TEN, are associated with specific genetic markers.
Key findings show significant associations between CYP2C9*3 and HLA alleles with SCARs induced by antiseizure medications.
Analysis of pharmacogenomic data included multiple studies examining the predictive potential of genetic variants.
Results highlight the importance of genetic testing in reducing hypersensitivity reactions in patients with epilepsy.],
simple_explanation
Patients with epilepsy sometimes have severe allergic reactions to certain seizure medications. Pharmacogenomics is the study of how our genes affect our response to drugs. This research found that specific gene markers can predict who might be at risk for these severe side effects from medications like carbamazepine and phenytoin. This means doctors could use genetic testing to help choose safer treatments for individual patients. 🚑

Abstract

Epilepsy is the second most common neurological condition worldwide, characterized by recurrent, unprovoked, self-limiting seizures of genetic, acquired, or unknown origin. The objective was to describe the pharmacogenomic markers associated with hypersensitivity reactions induced by aromatic antiseizure medications. This review explored the pharmacokinetics, pharmacogenomics of CYP2C9 and HLA associated with hypersensitivity reactions, immunopathogenesis and its clinical implications. The included studies applied odds ratio (OR), 95% confidence interval (95% CI) and p value, as association statistics between severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). An association study was found between CYP2C19*2 and SCARs induced by carbamazepine, phenytoin and phenobarbital. Five studies of CYP2C9*3 associated with phenytoin-induced SCARs, four studies of CYP2C9*3 , HLA-B*13:01 , HLA-B*15:02 , HLA-B*51:01 and HLA-B*55:01 HLA-B*46:01 and HLA-B*56:02/04 associated with phenytoin-induced SCARs. Likewise, six studies found an association between HLA-B*15:02 and carbamazepine-induced SJS/TEN, four studies associated HLA-A*02:07 , HLA-A*24:02 , HLA-A*33:03 , HLA-B*15:02 , HLA-B*44:03 with lamotrigine-induced SCARs, one study associated HLA-A*02:01 , HLA-B*35:01 , HLA-C*04:01 , and HLA-C*08:01 with lamotrigine- and phenytoin-induced SCARs. Three association studies between HLA-A*02:01 , HLA-A*11:01 , HLA-A*24:02 , HLA-B*15:02 , HLA-B*38:01 , HLA-B*40:02 and HLA-DRB1*03:01 with SCARs induced by carbamazepine, lamotrigine and phenytoin. Published scientific evidence demonstrates that CYP2C9*3 and various HLA alleles are associated with severe cutaneous adverse reactions such as toxic epidermal necrolysis and Stevens-Johnson syndrome. Neurologists should consider these allelic variants as predictive and preventive genetic biomarkers of severe adverse reactions to carbamazepine, phenytoin, phenobarbital, and lamotrigine, especially in Asian populations.

Ask AI

Helpful

Bookmark

View Full Paper